IRVINE, Calif.–(BUSINESS WIRE)–JenaValve Technology, Inc., a developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced U.S. Food and Drug Administration (FDA) approval of expansion of its Investigational Device Exemption (IDE) feasibility studies for the JenaValve Pericardial TAVR System with the Everdur™ transcatheter heart valve (THV) and […]
Tag: JenaValve
JenaValve Technology Initiates U.S. Patient Enrollment in Early Feasibility Study of Next-Generation TAVR System for the Treatment of Severe Aortic Stenosis and Severe Aortic Regurgitation
IRVINE, Calif.–(BUSINESS WIRE)–JenaValve Technology, Inc., a developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced initiation of patient enrollment in the Early Feasibility Study (EFS) of its next generation JenaValve Pericardial TAVR System using the Everdur™ transcatheter heart valve (THV) and CoronatixTMTransfemoral Delivery Catheter at NewYork-Presbyterian/ […]
JenaValve Technology Implants Initial Patients in CE Mark Study for the Treatment of Severe Aortic Regurgitation with Next-Generation TAVR System
IRVINE, Calif.–(BUSINESS WIRE)–JenaValve Technology, Inc., a developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced initiation of patient enrollment and implantations associated with the CE Mark study of its next generation JenaValve Pericardial TAVR System using the CoronatixTM Transfemoral Delivery Catheter for the percutaneous treatment of patients […]
JenaValve Technology Continues CE Mark Study Treating Severe Aortic Stenosis with Next-Generation System; Patient Enrollment and Successful Implantations with the Everdur™ Pericardial Aortic Valve and Coronatix™ Delivery Catheter
IRVINE, Calif.–(BUSINESS WIRE)–JenaValve Technology, Inc., a developer, manufacturer and marketer of differentiated transcatheter aortic valve replacement (TAVR) systems for the treatment of aortic valve disease, today announced successful patient enrollment in the CE Mark study of the next generation JenaValve Pericardial TAVR System utilizing the Coronatix™ Transfemoral Delivery Catheter for […]
JenaValve Technology Appoints Keith D. Dawkins, M.D., as Board Member
IRVINE, Calif.–(BUSINESS WIRE)–JenaValve Technology, Inc., a developer, manufacturer and marketer of differentiated transcatheter aortic valve replacement (TAVR) systems for the treatment of aortic valve disease, today announced the appointment of veteran medical device executive Keith D. Dawkins, M.D., as a new JenaValve board member. “As JenaValve advances its clinical development […]
JenaValve Technology Appoints Keith D. Dawkins, M.D., as Board Member
IRVINE, Calif.–(BUSINESS WIRE)– JenaValve Technology, Inc., a developer, manufacturer and marketer of differentiated transcatheter aortic valve replacement (TAVR) systems for the treatment of aortic valve disease, today announced the appointment of veteran medical device executive Keith D. Dawkins, M.D., as a new JenaValve board member. “As JenaValve advances its clinical development […]
JenaValve Raises $5 Million
JenaValve raises $5m FEBRUARY 6, 2018 BY FINK DENSFORD of MassDevice As first reported by Fink Densford of MassDevice: JenaValve Technology has raised $4.9 million in a new round of debt financing, according to an SEC filing posted this week. The Irvine, Calif.-based company is one of several smaller players looking to enter the […]
JenaValve Technology Appoints Laura A. Brenton as Vice President of Clinical and International Market Development
Feb. 2, 2018 14:00 UTC IRVINE, Calif.–(BUSINESS WIRE)– JenaValve Technology, Inc., a developer, manufacturer and marketer of differentiated transcatheter aortic valve replacement (TAVR) systems for the treatment of aortic valve disease, today announced the appointment of veteran medical device executive Laura A. Brenton as Vice President of Clinical and International Market […]
Recent
Popular
- No commented posts yet